143
Participants
Start Date
October 29, 2009
Primary Completion Date
April 18, 2011
Study Completion Date
April 18, 2011
SPD489 (Lisdexamfetamine dimesylate)
Oral, 20, 30, 40, 50, 60, and 70mg capsules, once daily
Matching placebo
oral, once daily
Richmond Behavioral Associates, Staten Island
Paramount Clinical Research, Bridgeville
Lehigh Center for Clinical Research, Allentown
Suburban Research Associates, Media
North Carolina Neuropsychiatry, PA, Chapel Hill
Richard H. Weisler, MD, PA & Associates, Raleigh
Duke University Medical Center, Durham
Carman Research, Smyrna
Atlanta Institute of Medicine & Research, Atlanta
Clinical Neuroscience Solutions, Inc., Jacksonville
Amit Vijapura, MD, Jacksonville
Clinical Neuroscience Solutions, Inc., Orlando
Scientific Clinical Research, Inc., North Miami
Patient Priority Clinical Sites, LLC, Cincinnati
Capstone Clinical Research, Libertyville
Joliet Center for Clinical Research, Joliet
PsychCare Consultants Research, St Louis
St. Charles Psychiatric Associates, Saint Charles
Psychiatric Associates, Overland Park
Premier Psychiatric Research Institute, LLC, Lincoln
University Hills Clinical Research, Irving
FutureSearch Trials of Dallas, LP, Dallas
Bayou City Resesarch, LTD, Houston
Red Oak Psychiatry Associates, PA, Houston
Wharton Research Center, Wharton
R/D Clinical Research, Inc., Lake Jackson
Pharmacology Research Center, Los Alamitos
Excell Research, Oceanside
Sun Valley Research Center, Imperial
Neuropsychiatric Resesarch Center of Orange County, Santa Ana
Northwest Clinical Research Center, Bellevue
Connecticut Clincal Research, Cromwell
AccelRx Research, Fall River
Lead Sponsor
Shire
INDUSTRY